BDBM185216 US10011588, Example 32::US10689373, Example 32::US9156829, 32

SMILES Fc1cccc(c1C(=O)N[C@H]1CCC[C@@H]1Nc1cnc(cn1)C(F)(F)F)-n1nccn1

InChI Key InChIKey=VQVAQBNKAOTWSZ-STQMWFEESA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 185216   

TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50:  32nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50: >1.00E+4nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50:  32nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50:  32nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent